increment color boost buyback
publish first look note result earlier today link
addit takeaway call although littl lh could avoid
impact ransomwar hurrican adj ep core
growth compani someth cash debt
pay tax payment share buyback chiefli
 pama impact track expect unlik link lh
highlight commerci price pressur higher patient concess addit
headwind reason shortfal expect volum growth
slow vs lh expect increas benefit organ volum
growth trade-off pressur revenue per requisit
initi comment underscor mani put take
lh reassur investor unh/aet contractu chang see signific
price compress net volum loss primarili
hospit lab face pama pressur lh hope see opportun
consolid lh begin new round cost initi provid color
plan organiz chang next phase launchpad program next
quarter covanc quarterli net book-to-bil vs
bode well still room cdd margin improv covanc
launchpad track deliv revenu synergi chiltern acquisit
net save covanc launchpad overal lh expect
deliv modest ep growth inclus buyback margin contract due
volum price headwind acceler growth beyond
adjust est better visibl trim po
updat guidanc link model revenu
adj ep modest gm model
revenu adj ep
trim po still base sotp multipl remain
optimist opportun lh reiter buy rate
net dbt
lab bitter cro sugar capit
deploy spice recip
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lh second-largest clinic laboratori
 intern invest acquisit
compani expand clinic diagnost
technolog offer better insul
growth rate lh also expand contract
research organ industri
acquisit covanc chiltern account
market share global
clinic lab oper highli competit
price-deflationari environ howev see
upsid potenti elev lab consolid
catalyz medicar reimburs cut pama
retail clinic opportun monet lab
data labcorp also diversifi faster
grow drug develop industri
acquisit covanc chiltern account
market share global
price object base sotp analysi weight averag
lab ebitda estimate cro ebitda estimate
roughli in-lin clinic lab cro peer group current trade see
upsid potenti elev lab consolid catalyz medicar reimburs
cut pama retail clinic opportun monet data lab
cro busi
upsid risk faster expect materi hospit lab consolid
trend smaller expect share loss contract significantli faster
cro growth margin improv
downsid risk greater expect price headwind lower expect test
volum growth competit execut risk integr risk data privaci risk
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
